David M. Pariser, M.D.
Dr. David Pariser is an active dermatologist and a founding board member of the International Hyperhidrosis Society (IHHS). He is a professor in the Department of Dermatology at Eastern Virginia Medical School in Norfolk, Virginia, where he is also the senior physician with Pariser Dermatology Specialists, Ltd., a private group practice of 12 Dermatologists, 7 Physician Assistants and 1 Nurse Practitioner. Dr. Pariser has been an American Academy of Dermatology (AAD) fellow since 1977 and was elected 2009-2010 president of the AAD (which represents more than 16,000 member physicians worldwide). Additionally, Dr. Pariser is an internationally renowned speaker on a variety of dermatologic issues and has participated in over 350 funded clinical trials.
Dr. Pariser has treated hundreds of hyperhidrosis patients and has lectured about the mechanism, diagnosis, and treatment of hyperhidrosis at numerous professional education forums on behalf of the IHHS, the AAD, and other dermatological associations. He is the consummate researcher and is continuously pursuing new treatment methods that will improve the quality of life of his patients. Dr. Pariser feels that, in his 37 years of practice, the patients who have given him the most inspiration are the hyperhidrosis sufferers whose lives he has been able to improve.
Head of Investment Banking, Triad Securities Corp., Andy is focused on M&A and Strategic life science transactions with a focus on the specialty pharmaceutical sector. Prior to joining Triad Securities, he was a Managing Director at Roberts Mitani, LLC from July 2011 through December 2013. From May 1984 through June 2011, Andy served as President of Corporate Development Specialists Inc., a firm which provided advisory services to pharmaceutical, device, consumer and biomedical companies. During the past three decades, Andy has worked with clients on a variety of merger, acquisition and product licensing agreements and has successfully consummated over 100 transactions, with an aggregate value exceeding $5 Billion. Andy has particular expertise in dermatology, where he has been the lead advisor on more than forty consummated transactions. Andy received a B.A. from Colgate University, a Masters in accounting from NYU Stern School of Business, and an MBA from University of Chicago Graduate School of Business.
Jonathan Wilkin, M.D. , Director, FDA Dermatology Division (retired)
Dermatology Regulatory Advisor
Dr. Wilkin, the founding director (retired) of the Division of Dermatology and Dental Products at the US Food and Drug Administration, remains active in regulatory matters after over 12 years of FDA service, which included membership on the FDA’s Dermatology Drugs Advisory Committee. Before going to the FDA, he was Director of Dermatology at the Ohio State University and Professor of Pharmacology and Medicine. He has over 130 publications in dermatology and clinical pharmacology. Dr. Wilkin has served as chairman of the medical advisory board for the National Rosacea Society since 1998 as well as having chaired their Expert Committees on the Classification and Staging System for Rosacea. He also serves on the American Academy of Dermatology’s (AAD) Ad Hoc Task Force on the Academy’s Efforts with FDA and on their Environment and Drugs Committee.
William H. Eaglstein, M.D.
Dr. Eaglstein is past professor and chairman of dermatology at the University of Pittsburgh and at the University of Miami, where he is currently chairman emeritus. Since 2004 he has worked in industry at Ivax Pharmaceuticals (President of Ivax Derm), Teva and Stiefel Pharmaceuticals ( Vice President of Research ) and Stiefel a GSK company (Vice President of New Product Assessment and External Research). He is currently an independent consultant and serves as a volunteer advisor for the Stanford School of Medicine SPARK program. His medical/scientific interests include wound healing, drug development, skin infections, UV inflammation and inflammatory diseases such as psoriasis and acne. Dr. Eaglstein has been a Robert Wood Johnson Health Policy Fellow, Chairman of an FDA skin advisory panel and on the National Institute of Arthritis, Musculoskeletal and Skin Diseases Advisory Panel. He continues his interest in health and regulatory policy. His hobbies include contemporary art and bicycling. He resides with his wife, Janet, in Menlo Park, California.
Zoe Diana Draelos, M.D.
Dr. Draelos is a practicing board-certified dermatologist and a Fellow of the American Academy of Dermatology with a research interest in cosmetics, toiletries, and biologically active skin medications. She is in solo private practice in High Point, North Carolina, and a Consulting Professor of Dermatology at Duke University. She has contributed chapters to 32 textbooks, served as the principle investigator on 274 studies, written 270 published papers, serves on 8 journal editorial boards, functions as the editor-in-chief of the Journal of Cosmetic Dermatology, and was a past member of the Board of Directors of the American Academy of Dermatology and the American Society for Dermatologic Surgery. She is Vice-President Elect of the American Academy of Dermatology. She received a lifetime achievement award from Health Beauty America for her research and the 2008 DermArts award for her contributions to dermatology. In 2010, she received the Albert Kligman Innovation Award.
Howard J. Maibach, M.D.
Dr. Maibach has been a Professor of Dermatology at the University of California, San Francisco (UCSF) since 1973 and also serves as its Vice Chairman of the Department of Dermatology. Founder of the Psoriasis Clinic at UCSF. Dr. Maibach is known worldwide for his expertise in dermatology and dermatological therapy. He is an honorary member of dermatologic societies of many countries. He is a recognized expert in the field of dermatology and specifically, dermatopharmacology and dermatotoxicology. Dr. Maibach has published more than 1900 papers and books on the various subjects in dermatology.
Christopher E.M. Griffiths, M.D.
Chris Griffiths was appointed to the Foundation Chair in Dermatology at the University of Manchester in 1994 and is an honorary consultant dermatologist at Salford Royal NHS Foundation Trust. Dr. Griffiths is co-founder of the International Psoriasis Council and is its President-Elect. He received the psoriasis lifetime achievement award of the American Skin Association in 2009. The Times of London named him as one of the UK’s Top 200 doctors in 2010 and in 2011 he was appointed as an NIHR Senior Investigator and elected to Fellowship of the Academy of Medical Sciences. Professor Griffiths has been President of the British Association of Dermatologists (2004-5); European Dermatology Forum (2010-11) and; British Society for Investigative Dermatology (1997-2000). He serves on the editorial boards of eight scientific journals and is an Associate Editor of the Journal of Investigative Dermatology. He has published 418 Pubmed cited articles in scientific journals and has an H-Index of 62. Professor Griffiths is co-editor of Rook’s Textbook of Dermatology and his research interests cover all aspects of psoriasis and skin ageing.
Eric Simpson, M.D., M.C.R
Dr. Simpson specializes in all aspects of general dermatology with special interests in moderate-to-severe atopic dermatitis (eczema), psoriasis and skin cancer. As Director of Clinical Research at Oregon Health and Science University's Dermatology Department, he is actively involved in clinical research and is currently funded by the National Institute of Health to study new approaches for eczema treatment and prevention.Dr. Simpson is a member of the scientific advisory committee of the National Eczema Association.Dr. Simpson has published in several peer-reviewed journals and has spoken at national and international conferences.
Victor J. Bauer, Ph.D. , President of Hoechst-Roussel (retired)
Dr. Bauer has more than 35 years of pharmaceutical product development and management experience with extensive US and international pharmaceutical businesses. He has a broad background in research, pre-clinical and clinical development, regulatory aspects of drug and biologics approval, intellectual property management, licensing, and executive management. Dr. Bauer was most recently Executive Vice President and Chief Scientific Officer at Concordia Pharmaceuticals, Inc. Prior to Concordia, Dr. Bauer was previously President of Hoechst-Roussel Pharmaceuticals, Inc. (Aventis). Dr. Bauer also serves as a Board Director at Titan Pharmaceuticals.